Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa
JEADV Clinical Practice · 2026-06 · 5 (2) · 648-650
DOI: 10.1002/jvc2.70225 ↗Kurz gefasst
Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 04.12.2025. Verfasst von Shiho Mori und 2 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Dapsone is a potent antibacterial agent used as a first‐line treatment for leprosy and employed also as an anti‐inflammatory agent. Additionally, dapsone is used for a variety of other cutaneous conditions. Herein, we report a case of intermediate junctional epidermolysis bullosa that improved significantly with oral 4,4’‐diamino‐diphenyl sulfone (dapsone).
Zitieren
APA
Mori, S., Fujimoto, M., & Tamai, K. (2026). Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa. JEADV Clinical Practice, 5(2), 648-650. https://doi.org/10.1002/jvc2.70225
Vancouver
Mori S, Fujimoto M, Tamai K. Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa. JEADV Clinical Practice. 2026;5(2):648-650. doi:10.1002/jvc2.70225
BibTeX
@article{Mori2026,
author = {Mori, Shiho and Fujimoto, Manabu and Tamai, Katsuto},
title = {Response to Oral Dapsone in a Patient With Generalised Junctional Epidermolysis Bullosa},
journal = {JEADV Clinical Practice},
year = {2026},
volume = {5},
number = {2},
pages = {648--650},
doi = {10.1002/jvc2.70225}
}
EUVIMED